Tibet Rhodiola Pharmaceutical Holding Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

March 16, 2025

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Full Year 2024 Results

Key Financial Results

Revenue: CN¥2.81b (down 11% from FY 2023).
Net income: CN¥1.05b (up 31% from FY 2023).
Profit margin: 38% (up from 26% in FY 2023). The increase in margin was driven by lower expenses.
EPS: CN¥3.26 (up from CN¥2.49 in FY 2023).

earnings-and-revenue-growth — SHSE:600211 Earnings and Revenue Growth March 16th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tibet Rhodiola Pharmaceutical Holding EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 2.5%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare industry in China.

Performance of the Chinese Healthcare industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Tibet Rhodiola Pharmaceutical Holding.

If you're looking to trade Tibet Rhodiola Pharmaceutical Holding, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Tibet Rhodiola Pharmaceutical Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.